Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
Journal of Atherosclerosis and Thrombosis · 01.05.2023 · 30 (5) · 531-557
DOI: 10.5551/jat.cr006 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.05.2023. Verfasst von Mariko Harada-Shiba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Osaka Medical and Pharmaceutical University. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
As atherosclerosis begins in childhood, early diagnosis and treatment of familial hypercholesterolemia (FH) is considered necessary. The basic diagnosis of pediatric FH (under 15 years of age) is based on hyper-low-density lipoprotein (LDL) cholesterolemia and a family history of FH; however, in this guideline, to reduce overlooked cases, "probable FH" was established. Once diagnosed with FH or probable FH, efforts should be made to promptly provide lifestyle guidance, including diet. It is also important to conduct an intrafamilial survey, to identify family members with the same condition. If the level of LDL-C remains above 180 mg/dL, drug therapy should be considered at the age of 10. The first-line drug should be statin. Evaluation of atherosclerosis should be started using non-invasive techniques, such as ultrasound. The management target level is an LDL-C level of less than 140 mg/dL. If a homozygous FH is suspected, consult a specialist and determine the response to pharmacotherapy with evaluating atherosclerosis. If the response is inadequate, initiate lipoprotein apheresis as soon as possible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Center, Osaka Medical and Pharmaceutical University.
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute.
- Department of Pediatrics, Faculty of Medicine, Saitama Medical University.
- Faculty of Nursing and Medical Care, Keio University.
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine.
- Department of Pediatrics, School of Medicine, University of Yamanashi.
Zitieren
APA
Harada-Shiba, M., Ohtake, A., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., & Yamamoto, Y. (2023). Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis, 30(5), 531-557. https://doi.org/10.5551/jat.cr006
Vancouver
Harada-Shiba M, Ohtake A, Sugiyama D, Tada H, Dobashi K, Matsuki K, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. Journal of Atherosclerosis and Thrombosis. 2023;30(5):531-557. doi:10.5551/jat.cr006
BibTeX
@article{HaradaShiba2023,
author = {Harada-Shiba, Mariko and Ohtake, Akira and Sugiyama, Daisuke and Tada, Hayato and Dobashi, Kazushige and Matsuki, Kota and Minamino, Tetsuo and Yamashita, Shizuya and Yamamoto, Yukiyo},
title = {Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2023},
volume = {30},
number = {5},
pages = {531--557},
doi = {10.5551/jat.cr006}
}
EUVIMED